Summary
Treatment of rats with cisplatin (4 mg kg-1body wt i.p. injection) induced variations of urinary kallikrein excretion (UKE). Three phases were observed: a transient increase of UKE one day after injection, followed by a decrease up to 10 days suggesting an altered biosynthesis and a recovery phase with return to normal control values, 21 days after injection. Early morphological lesions were observed in proximal tubule cells on day 1; severe changes and tubular necrosis were observed in the following days. Less marked changes were also present in distal tubules but the vacuolated and desquamated cells appeared in the lumen of the tubules. By immunocytochemical methods, kallikrein was observed in connecting tubule cells, but also in some proximal tubule cells and along the endothelial side of the glomerular basement membrane and urinary space of glomeruli. An intense labelling was present in desquamated epithelial cells in dilated lumen of tubules. This study provides evidence of the presence of immunoreactive kallikrein in the glomerulus, already reported during acute failure, and confirms the use of urinary kallikrein measurements as a useful non-invasive index to assess a possible nephrotoxic effect at the distal level.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amundsen, A., Pulter, J., Frieberger, P., Knos, M., Larsbraten, M. & Claeson, G. (1978) Methods for the determination of glandular kallikrein by means of a chromogenic tripeptide substrate. Adv. Exp. Med. Biol. 120A, 83–96.
Bascands, J. L., Girolami, J. P., Pécher, C., Cabos, G., Moatti, J. P., Suc, J. M. & Manuel, Y. (1987) Short lasting increase in urinary specific kallikrein activity during long-term administration of furosemide. Agents Actions 22, 302–309.
Bompart, G., Pécher, C., Prevot, D. & Girolami, J. P. (1990) Mild renal failure induced by subchronic exposure to molybdenum: urinary kallikrein excretion as marker of distal tubular effects. Toxicol. Lett. 52, 293–300.
Bompart, G., Orfila, C. & Girolami, J. P. (1991) Distal nephrotoxicity of cisplatin demonstrated by urinary kallikrein excretion and morphological study in rats. Toxicology 69, 121–132.
Carretero, O. A. & Scicli, A. G. (1978) The renal kallikrein kinin system in human and in essential hypertension. Klin. Wochenschr. 56, 113–125.
Choie, D. D., Longnecker, D. S. & Delcampo, A. A. (1981) Acute and chronic cisplatin nephropathy in rats. Lab. Invest. 44, 397–402.
Daugaard, G., Abildgaard, U., Larsen, S., Holdstein-Rathlou, N. H., Amtorp, O., Olesen, H. P. & Leyssac, P. P. (1987) Functional and histopathological changes in dog kidneys after administration of cisplatin. Renal Physiol. 10, 54–64.
Dobyan, D. C., Levi, J., Jacobs, C., Kosek, J. & Weiner, M. W. (1980) Mechanisms of cisplatinum nephrotoxicity. II. Morphologic observation. J. Pharmacol. Exp. Ther. 213, 551–556.
Girolami, J. P., Alhenc-Gelas, F., Dos Reiss, M. L., Bascands, J. L., Suc, J. M., Corvol, P. & Menard, J. (1986) Hydrolysis of rat high molecular weight kininogen: identification of bradykinin as the kinin formed. Adv. Exp. Biol. Med. 198, A 137–145.
Girolami, J. P., Bascands, J. L., Pécher, C. & Suc, J. M. (1987) Direct radioimmunoassay of rat urinary kallikrein: its application to the determination of active and inactive concentration after HPLC analysis. J. Immunoassay 8, 115–130.
Girolami, J. P., Bascands, J. L., Pécher, C., Cabos, G., Moatti, J. P., Mercier, J. M., Haguenoer, J. M. & Manuel, Y. (1989a) Renal kallikrein excretion as a distal nephrotoxicity marker during cadmium exposure in rats. Toxicology 55, 117–129.
Girolami, J. P., Orfila, C., Pécher, C., Cabos-Boutot, G., Bascands, J. L., Moatti, J. P., Adam, A. & Collé, A. (1989b) Inverse relationship between renal and urinary kallikrein during chromate-induced acute renal failure in rat urinary kallikrein excretion as a possible recovery index. Biol. Chem. Hoppe Seyler 370, 1315–1323.
Girolami, J. P., Orfila, C., Cabos-Boutot, G., Pécher, C., Bascands, J. L. & Collé, A. (1990) Early acute effect of mercuric chloride on synthesis and release of kallikrein and on distal tubular morphology of rat renal cortical slices. Renal Physiol. Biochem. 13, 223–232.
Jones, T. W., Chopra, S., Kaufman, J. S., Flamenbaum, W. & Trymp, B. J. (1985) Cis-diammine dichloroplatinium (II) induced acute renal failure in the rat. Correlation of structural and functional alterations. Lab. Invest. 52, 363–374.
Laurell, G., Engstrom, B., Hirsch, A., Bagger-Sjobäck, D. (1987) Ototoxicity of cisplatin. Int. J. Androl. 10, 359–362.
Lippman, A. J., Helson, C., Helson, L. & Krakoff, J. H. (1973) Clinical trials of cis-diammine dichloroplatinum (NSC-119875). Cancer Chemother. Rep. 57, 191–200.
Litterst, C., Smith, J. H., Smith, M. A., Wozumi, J. & Copley, M. (1985) Sensitivity of urinary enzymes as indicators of renal toxicity of the anticancer drug cisplatin. Uremia Invest. 9, 111–117.
Madias, N. E. & Harrington, J. T. (1978) Platinum nephrotoxicity. Am. J. Med. 65, 307–314.
Marchetti, J., Imbert-Teboul, M., Alhenc-Gelas, F., Allergrini, J., Menard, J. & Morel, F. (1984) Kallikrein along the microdissected nephron: a micromethod for its measurements: effect of adrenalectomy and DOCA treatment. Pflugers Arch. 40, 27–31.
Margolius, H. S. (1989) Tissue kallikreins and kinins: regulation and roles in hypertensive and diabetic diseases. Ann. Rev. Pharmacol. Toxicol. 2, 343–364.
Offerman, J. J. G., Meyer, S., Skijfer, D. T., Mulder, N. H., Donker, A. J. M., Koops, H. S. & VanDerHem, G. K. (1984) Acute effects of cis-diammine dichloroplatinum (CDDP) on renal function. Cancer Chemother. Pharmacol. 12, 36–38.
Orfila, C., Bascands, J. L., Suc, J. M. & Girolami, J. P. (1988) Localization of renal kallikrein immunoreactive-like substance in rat ureter. J. Histochem. Cytochem. 36, 1463–1469.
Orfila, C., Suc, J. M. & Girolami, J. P. (1992) Evidence for intrarenal kallikrein storage during chromate-induced acute renal failure. Histochemistry 97, 293–301.
Rosenberg, B., VanCam, L., Trasko, J. H. & Mansour, V. H. (1969) Platinum compounds: a new class of potent antitumor agents. Nature 222, 385–386.
Safirstein, R., Winston, J., Moel, D., Dikman, S. & Guttenplan, J. (1987) Cisplatin nephrotoxicity: insights into mechanism. Int. J. Androl. 10, 325–346.
Simson, J. A. V., Spicer, S. S., Chao, J., Grimm, L. & Margolius, H. S. (1979) Kallikrein localization in rodent salivary glands and kidney with the immunoglobulin-enzyme bridge technique. J. Histochem. Cytochem. 27, 1567–1576.
Vio, C. P. & Figueroa, C. D. (1985) Subcellular localization of renal kallikrein by ultrastructural immunocytochemistry. Kidney Int. 28, 36–42.
Vio, C. P., Loyola, S. & Velarde, V. (1992) Localizations of components of the kallikrein-kinin system in the kidney: relation to renal function. Hypertension 19, (suppl. II) 10–16.
Ward, J. M. & Fauvies, K. (1976) The nephrotoxic effects of cis-diammine dichloroplatinum (II)-(NSC-119875) in male 344 rats. Toxicol. Appl. Pharmacol. 38, 535–547.
Xiong, W., Chao, L. & Chao, J. (1989) Renal kallikrein in RNA localization by in situ hybridization. Kidney Int. 35, 1324–1329.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Orfila, C., Bompart, G., Lepert, J.C. et al. Renal immunolocalization of kallikrein in cisplatin nephrotoxicity in rats. Histochem J 25, 772–777 (1993). https://doi.org/10.1007/BF00211772
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00211772